

A. JANSSENS, MD, PHD



DEAR COLLEAGUES,

We are happy to offer you the fourth issue of the BJH 2025.

We have selected three manuscripts for **REVIEW HEMATOLOGY**. **A. Verstraete *et al.*** (Department of Cardiovascular diseases, University Hospitals Leuven, Leuven) describe “**Advancements in thrombophilia testing: The role of multi-gene panels in venous thromboembolism (VTE)**”. Although a multi-gene panel for thrombophilia testing in patients with VTE can reveal previously undetected variants that are not identified by conventional thrombophilia tests, variants of uncertain significance are found highlighting the need for international collaboration to characterise and re-classify these variants. Further research is essential to evaluate the therapeutic implications of multi-gene panel testing in patients with VTE. The second review, “**The role of UBTF-TD mutations in paediatric acute myeloid leukaemia and myelodysplastic syndrome**” by B. Decuyper *et al.* (Department of Paediatrics, Ghent University Hospital, Ghent), consolidates current knowledge on UBTF-TD mutations, covering their molecular landscape, clinical implications and potential therapeutic considerations. The third review, “**Desensitisation as treatment option in patients with drug hypersensitivity**” by E.M. Hutten *et al.* (Department of Internal Medicine and Allergology, UMCG, Groningen, The Netherlands), explains hypersensitivity reactions and desensitisation therapy for oncolytic agents and how to reach successful desensitisation so that cancer treatment is not compromised.

In **PHARMACOTHERAPY**, M. Zivkovic *et al.* highlight “**HMB-001: Novel treatment for Glanzmann thrombasthenia (GT)**”. HMB-001 is a bispecific antibody binding endogenous FVIIa and TLT-1 (a receptor on activated platelets) with improved haemostasis in vitro and a phase I trial. A phase II trial in GT is ongoing and the bispecific molecule will be tested in other coagulation disorders.

One case report has been selected for **HEMATOCASE**. “**Anti-IL6 receptor antibody for the treatment of immune checkpoint-related haemophagocytic lymphohistiocytosis (irHLH)**” by L. Hindryckx *et al.* (Department of Medical Oncology, CHU Helora, Haine-Saint-Paul). This report shows that tocilizumab appears to be an efficient second-line therapy for irHLH refractory to steroids.

In **CONGRESS NEWS**, E. Dewulf, (Ariez International BV, Ghent) selects topics as the prognostic value of early cytomegalovirus clearance, novel therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease, the efficacy of post-transplant cyclophosphamide across donor types in acute lymphoblastic leukaemia, and much more.

In **JOURNAL SCAN**, T. Verbeek (Ariez International BV, Ghent) aims to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology.

Finally, J. Blokken (Ariez International BV, Ghent) summarises the **NEW REIMBURSEMENTS** in haematology.

We wish you enjoyable summer holidays,

Ann Janssens, MD, PhD
Editor-in-Chief